Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Scandinavian Journal of Gastroenterology

• Publication date

  2011-02-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/00365521.2010.536254PMID 21087119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

  2010cited by this paper
• Comment on ‘Predicting the response to infliximab from trough serum levels’

  2010influential reference
• [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].

  2010cited by this paper
• Editorial: Anti-TNF Treatment in Crohn's Disease: Toward Tailored Therapy?

  2010cited by this paper
• Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

  2009cited by this paper
• Biological therapies for inflammatory bowel diseases.

  2009cited by this paper
• Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

  2009influential reference
• Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review

  2009cited by this paper
• Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement.

  2008cited by this paper
• Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

  2008cited by this paper
• Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

  2008cited by this paper
• Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

  2008cited by this paper
• Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

  2008cited by this paper
• Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

  2008influential reference
• Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.

  2007cited by this paper
• Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

  2007cited by this paper
• American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

  2007cited by this paper
• Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

  2007cited by this paper
• EDITOR’S QUIZ: GI SNAPSHOT

  2007cited by this paper
• Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.

  2006cited by this paper
• Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.

  2006cited by this paper
• Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.

  2006cited by this paper
• Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

  2006cited by this paper
• Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.

  2006cited by this paper
• Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

  2004cited by this paper
• Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• Anti-IFN BAb and NAb antibodies

  2003influential reference
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003influential reference
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

  2002cited by this paper
• Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease

  2001cited by this paper
• The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs.

  2000cited by this paper
• Quantitative angiographic measurements of isolated left anterior descending coronary artery stenosis. Correlation with exercise echocardiography and technetium-99m 2-methoxy isobutyl isonitrile single-photon emission computed tomography.

  1995cited by this paper
• Course of ulcerative colitis: analysis of changes in disease activity over years.

  1994cited by this paper
• Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence.

  1992cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Management of Anti-drug Antibodies Against TNF-Inhibitors in Sarcoidosis Patients.

  2025cites this paper
• Pan-immune-inflammation value and systemic immune-inflammation index predict the clinical efficacy of biological agents in Crohn's disease.

  2025cites this paper
• Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients

  2025cites this paper
• The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring

  2025cites this paper
• Infliximab Therapeutic monitoring by tryptic peptide LC-MS/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time

  2024cites this paper
• Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

  2024cites this paper
• Oral manifestations of Crohn disease managed with ustekinumab: A case report.

  2024cites this paper
• Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort.

  2023cites this paper
• Proposed 1 WHO International Reference Panel for Infliximab anti-drug antibodies

  2022cites this paper
• Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease

  2022cites this paper
• Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study

  2022cites this paper
• A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease.

  2022cites this paper
• The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis

  2022cites this paper
• Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

  2021cites this paper
• Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.

  2021cites this paper
• The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease

  2021cites this paper
• Measurement of Serum Antibodies to Selected Biologic Agents

  2021cites this paper
• High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases

  2021cites this paper
• Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study

  2021cites this paper
• A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays

  2021cites this paper
• Utility, promise, and limitations of liquid chromatography‐mass spectrometry‐based therapeutic drug monitoring in precision medicine

  2021cites this paper
• PREDICTORS OF INFLIXIMAB TROUGH CONCENTRATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS USING A REPEATED MEASURES DESIGN.

  2020cites this paper
• Intermittent Appearance of Antibodies to Infliximab Is Not Associated With Reduced Efficacy in Patients With Inflammatory Bowel Diseases

  2020cites this paper
• Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients

  2020cites this paper
• Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

  2020cites this paper
• Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study

  2020cites this paper
• Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.

  2020cites this paper
• Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

  2020cites this paper
• Trough Levels of Infliximab at W6 Are Predictive of Remission at W14 in Pediatric Crohn Disease.

  2020cites this paper
• Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab.

  2020cites this paper
• Effective presentation of immunogenicity risk assessments and related data in regulatory dossiers.

  2019cites this paper
• Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

  2019cites this paper
• Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

  2019cites this paper
• Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.

  2019cites this paper
• Measurement of Serum Antibodies to Infliximab and Adalimumab

  2019cites this paper
• Absence of relationship between CDAI or CRP and infliximab exposure calls for objective Crohn's disease activity measures for the evaluation of treatment effects at treatment failure.

  2019cites this paper
• Measurement of Serum Antibodies to Infliximab, Adalimumab, Ustekinumab, and Vedolizumab

  2019cites this paper
• Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia

  2019cites this paper
• Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease

  2019cites this paper
• Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta‐analysis

  2019cites this paper
• Using data science to diagnose and characterize heterogeneity of Alzheimer's disease

  2019cites this paper
• Measurement of Serum Antibodies to Selected Biologic Agents

  2019cites this paper
• Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

  2018influential citation
• Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease

  2018cites this paper
• Infliximab use in ulcerative colitis flare with clostridium difficile infection: A report of two cases and literature review

  2018cites this paper
• Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?

  2018cites this paper
• Immunogenicity of biologics in inflammatory bowel disease

  2018cites this paper
• Quantitation of Infliximab and Detection of Antidrug Antibodies in Serum by Use of Surface Plasmon Resonance.

  2018cites this paper
• Measurement of Serum Antibodies to Infliximab and Adalimumab Effective : May 1 , 2018

  2018influential citation
• Measurement of Serum Antibodies to Infliximab and Adalimumab Effective : May 1 , 2018

  2018influential citation
• Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases

  2018cites this paper
• Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study

  2018cites this paper
• Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

  2018cites this paper
• Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay

  2018cites this paper
• The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease

  2017cites this paper
• Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

  2017cites this paper
• Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study

  2017cites this paper
• Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn’s disease: a systematic review and meta-analysis

  2017cites this paper
• Can We Predict the Efficacy of Anti-TNF-α Agents?

  2017cites this paper
• Proposal for an anti-TNF-exit strategy based on trough serum level.

  2017cites this paper
• Review article: consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases

  2017cites this paper
• NASPGHAN Clinical Report on Postoperative Recurrence in Pediatric Crohn Disease

  2017cites this paper
• Clinical performance of an infliximab rapid quantification assay

  2017cites this paper
• Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis

  2017cites this paper
• One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed

  2017cites this paper
• Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta‐analysis

  2017cites this paper
• Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease

  2017cites this paper
• Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease

  2017cites this paper
• Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease

  2017cites this paper
• Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease

  2017cites this paper
• Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease

  2017cites this paper
• Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis.

  2017cites this paper
• Therapeutic drug monitoring was helpful in guiding the decision‐making process for children receiving infliximab for inflammatory bowel disease

  2017cites this paper
• A review of six methods for monitoring infliximab concentrations and antibodies to infliximab
.

  2017cites this paper
• Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

  2017cites this paper
• Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease

  2017cites this paper
• Treatment options for patients with secondary loss of response to anti-TNF therapy

  2017cites this paper
• Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

  2017cites this paper
• Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.

  2017cites this paper
• Therapeutic drug monitoring guided anti-tumour necrosis factor therapy in inflammatory bowel disease (IBD): Gastroenterological Society of Australia (GESA)/ Australian IBD Association (AIBDA) consensus statements

  2017influential citation
• Optimal use of immunomodulator and biological therapy in Inflammatory Bowel Disease

  2017influential citation
• O maior índice de massa corporal e a presença de anticorpos antifármacos predizem a interrupção no uso de agentes anti‐TNF em pacientes sul‐coreanos com espondiloartrite axial

  2017cites this paper
• American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.

  2017influential citation
• Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines

  2017cites this paper
• Intra‐patient variability in adalimumab drug levels within and between cycles in Crohn's disease

  2017cites this paper
• Title : Measurement of serum antibodies to infliximab and adalimumab

  2017cites this paper
• Measurement of Serum Antibodies to Infliximab and Adalimumab

  2017cites this paper
• Measurement of Serum Antibodies to Infliximab and Adalimumab Effective : July 1 , 2017

  2017influential citation
• Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults

  2016cites this paper
• Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies.

  2016influential citation
• Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease

  2016cites this paper
• Use of anti-TNF drug levels to optimise patient management

  2016cites this paper
• Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration

  2016cites this paper
• Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease:

  2016cites this paper
• Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay

  2016cites this paper
• Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease

  2016cites this paper
• Optimizing anti-TNF therapy in inflammatory bowel disease

  2016influential citation
• Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology

  2016cites this paper
• Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays

  2016cites this paper
• Management of Acute Severe Colitis in Children With Ulcerative Colitis in the Biologics Era

  2016cites this paper